meta_pixel
Tapesearch Logo
Log in
What Next | Daily News and Analysis

TBD | A Vaccine Won’t Be the End

What Next | Daily News and Analysis

Slate Podcasts

Daily News, News, News Commentary

4.32.4K Ratings

🗓️ 25 September 2020

⏱️ 21 minutes

🧾️ Download transcript

Summary

As of Sept. 24, there are 42 vaccines in clinical trials on humans. At least 92 others are being developed but have not yet gone to trial. For months, the world has tracked the progression of these vaccines closely, with the expectation that once one arrives on the market, we can finally start to go back to normal. But, is that true? Does the world really look much different with an effective vaccine? Guest: Dr. Paul Offit, professor of pediatrics at the Children's Hospital of Philadelphia. Host Celeste Headlee   Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0

Since the genetic sequence for the coronavirus was first made public in January, scientists worldwide

0:10.4

have been working on developing a vaccine. Never before in history has it taken less than

0:16.0

several years for a new vaccine to be produced. Dr. Anthony Fauci says a COVID inoculation

0:22.0

could be available to the public as soon as next January. And this emphasis on speed has some

0:27.3

people worried that politicians are pressuring scientists to cut corners. But other people just want

0:33.8

to know how soon they can get in line. So where do you stand? People are being asked, would you get

0:40.6

a COVID-19 vaccine or set another way? Would you get a theoretical COVID-19 vaccine because there

0:45.2

is no COVID-19 vaccine? That's Dr. Paul Offit. Offit is the director of the Vaccine Education Center

0:52.0

at Children's Hospital of Philadelphia. He was also co-inventor of a rotavirus vaccine and serves

0:58.2

on the Vaccine Advisory Committee for the FDA. If you ask me that question, if you said, would I get

1:03.9

a COVID-19 vaccine? My answer to that would be not until I see the data. Let me see whether or not

1:09.9

my group is represented there, whatever it is, whether it's African-American or Latinx or obese or

1:16.1

healthcare worker or someone over 65. You want to see that your group is represented in the safety

1:21.6

data and the efficacy data. But Paul says that data may not come from months and when it does start

1:28.0

to trickle in, don't expect certainty. Instead, assume that you'll have to make educated guesses.

1:35.6

The question when you launch a medical product is not, do I know everything? The question is,

1:39.6

do you know enough to say that the benefits of this particular product, that way it's theoretical

1:44.7

risks? I mean, do you know enough to say that? Sometimes there's unpleasant surprises, but that's

1:50.9

the nature of medical breakthroughs. There's always learning curve.

1:56.3

Today on the show, selling the vaccine, when we finally get an FDA-approved inoculation,

2:02.3

we'll some refuse to get the shot. I'm Celeste Headley, filling in for Lizio Liri, and you're listening

2:08.5

to what next TBD? A show about technology, power, and how the future will be determined. Stay with us.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Slate Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Slate Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.